JPMorgan Chase & Co. Has $33.09 Million Position in Qiagen N.V. $QGEN

JPMorgan Chase & Co. trimmed its position in shares of Qiagen N.V. (NYSE:QGEN) by 40.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 740,649 shares of the company’s stock after selling 512,299 shares during the quarter. JPMorgan Chase & Co.’s holdings in Qiagen were worth $33,092,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in QGEN. Smartleaf Asset Management LLC boosted its position in Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after buying an additional 830 shares during the period. MAI Capital Management raised its stake in shares of Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after acquiring an additional 889 shares during the last quarter. Allworth Financial LP grew its stake in shares of Qiagen by 260.1% in the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after purchasing an additional 796 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Qiagen by 375.5% in the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after purchasing an additional 980 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in Qiagen by 64.0% in the third quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock valued at $71,000 after purchasing an additional 628 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Trading Up 1.5%

Shares of QGEN stock opened at $49.81 on Friday. The company has a market cap of $10.52 billion, a P/E ratio of 24.71, a PEG ratio of 2.39 and a beta of 0.67. The stock has a 50 day simple moving average of $50.01 and a two-hundred day simple moving average of $49.37. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. Qiagen N.V. has a fifty-two week low of $39.61 and a fifty-two week high of $57.81.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.61 by $0.01. The company had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 EPS. Research analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current year.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: DWS Investment disclosed a 2.76% voting stake in Qiagen — a notable institutional position that can lend support to the share price, raise confidence among other investors and prompt speculation about engagement or strategic influence. DWS Investment Discloses 2.76% Voting Stake in Qiagen
• Positive Sentiment: Reports show large volumes of Qiagen call options were purchased, indicating bullish positioning or short-term speculative interest that can amplify upward moves in the stock and attract momentum traders. Investors Buy Large Volume of Qiagen Call Options (NYSE:QGEN)
• Negative Sentiment: Zacks Research reduced EPS estimates across multiple near-term quarters and trimmed FY2026 and FY2027 forecasts (FY2026 cut from $2.57 to $2.51; FY2027 trimmed to $2.81 from $2.85), and lowered several quarterly estimates (Q1–Q3 2026 and Q2–Q3 2027). Those downgrades signal weaker near-term earnings growth expectations and could limit upside if revisions continue.

Wall Street Analyst Weigh In

Several brokerages have commented on QGEN. JPMorgan Chase & Co. lifted their target price on Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Robert W. Baird set a $53.00 price objective on Qiagen in a research note on Friday, February 6th. Barclays set a $58.00 target price on Qiagen and gave the company an “overweight” rating in a report on Friday, February 6th. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $55.20.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.